{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-26-000020","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2026-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.813475+00:00","generated_at":"2026-05-15T05:32:13.488387+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zentalis presents preclinical azenosertib data in TNBC; real-world ovarian cancer outcomes shown","bullets":["Azenosertib + enfortumab vedotin induced 87.5% complete responses in ADC-resistant TNBC PDX model; 5 of 8 mice had no progression after treatment stop.","Median PFS not reached for azenosertib+EV vs. 22 days for EV alone (HR=0.14, p<0.0001) in TOP1i-ADC-resistant model.","Real-world data: Cyclin E1-positive ovarian cancer patients had shorter time to next treatment (13.2–14.9 months) vs. Cyclin E1-negative (19.5 months), p=0.002.","Azenosertib monotherapy showed 42–99% tumor growth inhibition across 12 TNBC xenograft models.","Data presented at AACR 2026; company plans to explore azenosertib combinations post-ADC in TNBC."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-26-000020","json":"https://secwatch.observer/filing/0001725160-26-000020.json","markdown":"https://secwatch.observer/filing/0001725160-26-000020.md","text":"https://secwatch.observer/filing/0001725160-26-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000020/0001725160-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000020/zntl-20260417.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:32:13.488387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}